M
Michele Caraglia
Researcher at Seconda Università degli Studi di Napoli
Publications - 562
Citations - 24508
Michele Caraglia is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 67, co-authored 525 publications receiving 20615 citations. Previous affiliations of Michele Caraglia include Temple University & Magna Græcia University.
Papers
More filters
Journal ArticleDOI
S-Adenosylmethionine Inhibits Cell Growth and Migration of Triple Negative Breast Cancer Cells through Upregulating MiRNA-34c and MiRNA-449a
Alessandra Coppola,Concetta Paola Ilisso,Antonietta Stellavato,Chiara Schiraldi,Michele Caraglia,Laura Mosca,Giovanna Cacciapuoti,Marina Porcelli +7 more
TL;DR: In this paper, S-adenosyl-L-methionine (AdoMet) has been shown to upregulate miR-34c and miRNA-449a expression in both cell lines.
Journal ArticleDOI
Mutual Correlation between Non-Coding RNA and S-Adenosylmethionine in Human Cancer: Roles and Therapeutic Opportunities.
Laura Mosca,Francesca Vitiello,Luigi Borzacchiello,Alessandra Coppola,Roberta Veglia Tranchese,Martina Pagano,Michele Caraglia,Giovanna Cacciapuoti,Marina Porcelli +8 more
TL;DR: In this paper, a review summarizes the recent findings on the mechanisms by which AdoMet and miRNA/lncRNA exert their bioactivity, providing new insights to develop innovative and more efficient anticancer strategies based on the interactions between these epigenetic modulators.
Journal ArticleDOI
Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports
Liliana Montella,Raffaele Addeo,Vincenzo Faiola,Gregorio Cennamo,Rosario Guarrasi,Elena Capasso,Rosanna Mamone,Michele Caraglia,Salvatore Del Prete +8 more
TL;DR: Control of pain associated with bone tumors such as chondrosarcoma and chondroma may significantly improve from use of zoledronic acid, independently from tumor response to other treatments.
Journal ArticleDOI
Two faces for Janus: recombinant human erythropoiesis-stimulating agents and cancer mortality
TL;DR: The meta-analysis demonstrated that ESAs increased mortality by 17% during the active study periods and worsened overall survival in patients with cancer, however, 62% of patients evaluated in this analysis started the ESA therapy with basal hemoglobin values over that recommended by ASCO/ASH guidelines.
Journal ArticleDOI
Breast MALT lymphomas: a clinicopathological and cytogenetic study of 9 cases.
Giuseppina Liguori,Monica Cantile,Margherita Cerrone,Elvira La Mantia,Maurizio Di Bonito,Fabrizio Zanconati,Maria Pia Curcio,Gabriella Aquino,Anna La Mura,Rosa Giannatiempo,Annarosaria De Chiara,Angela Lombardi,Gerardo Botti,Antonio D'Antonio,Michele Caraglia,Renato Franco +15 more
TL;DR: The data indicate that MALT1 gene rearrangements are not rare in primary breast MALT lymphomas, and there was no evidence of BCL10 gene translocation in any of the neoplasms assessed.